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OBJECTIVES: To investigate the prevalence of potential drug interactions at the intensive care unit of a university
hospital in Brazil and to analyze their clinical significance.
METHODS: This cross-sectional retrospective study included 299 patients who had been hospitalized in the intensive
care unit of the hospital. The drugs administered during the first 24 hours of hospitalization, in the 50th length-of-
stay percentile and at the time of discharge were analyzed to identify potential drug-drug and drug-enteral
nutrition interactions using DRUG-REAXH software. The drugs were classified according to the anatomical
therapeutic chemical classification.
RESULTS: The median number of medications per patient was smaller at the time of discharge than in the 50th
length-of-stay percentile and in the first 24 hours of hospitalization. There was a 70% prevalence of potential drug
interactions at the intensive care unit at the studied time points of hospitalization. Most of the drug interactions
were either severe or moderate, and the scientific evidence for the interactions was, in general, either good or
excellent. Pharmacodynamic interactions presented a subtle predominance in relation to pharmacokinetic
interactions. The occurrence of potential drug interactions was associated with the number of medications
administered and the length of stay. Medications that induced cytochrome P450, drugs that prolong the QT interval
and cardiovascular drugs were pharmacotherapy factors associated with potential drug interactions.
CONCLUSION: The study showed that potential drug interactions were prevalent in the intensive care unit due to
the complexity of the pharmacotherapies administered. The interactions were associated with the number of drugs,
the length of stay and the characteristics of the administered medications.
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INTRODUCTION
Drugs are one of the health technologies that are essential
for the effectiveness of the care delivered at intensive care
units (ICUs). Due to the complexity of the pharmacotherapy
involved in the simultaneous use of several drugs and
various therapeutic classes, critically ill patients are at an
increased risk for drug interactions (DIs).1-3
ICU patients are particularly predisposed to the devel-
opment of drug interactions, and this predisposition is
complicated by disease severity and organ failure, both of
which can change the pharmacologic response to medica-
tions.4,5
The number of prescribed drugs is a risk factor for the
occurrence of a DI. Studies have demonstrated a positive
correlation between polypharmacy and DIs.6 Other deter-
minant factors for the occurrence of a DI include the
pharmacokinetic profile and the pharmacological character-
istics of the medications.1,7,8
DIs can cause undesirable patient responses, with effects
ranging from treatment inefficacy to serious adverse
events.1,4,9 However, the decision to prescribe two drugs
simultaneously is sometimes intentional, with the aim of
obtaining a specific pharmacological synergism.10
Thus, the objectives of the present study were to
investigate the prevalence of DIs in the ICU of a university
hospital in Brazil and to analyze the clinical significance of
their interactions.
METHODS
Study design, patients, and data collection
This cross-sectional retrospective study was developed at
Hospital das Clı´nicas, Federal University of Minas Gerais,
which is a tertiary hospital in Brazil. The investigation was
approved by the ethics committee at the university.
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All patients admitted to the hospital ICU between January
2007 and December 2007 were identified using the hospital’s
information system. Patients who met the following criteria
were included in the study: over 18 years of age, at least
5 days in the ICU and prescribed medications in the first
24 hours of hospitalization and in the 50th length-of-stay
percentile and discharged with two or more drugs. Of the
1,361 patients admitted to the ICU during 2007, 299 met the
inclusion criteria.
The demographic information, main diagnosis, comor-
bidities and laboratory and clinical data necessary to obtain
the SAPSII were extracted from the patients’ clinical history
records. Information regarding medications and enteral
nutrition administered at each of the three time points were
collected from the medical prescription documentation, and
other observations were obtained from the administration
notes made by the nurse.
The drugs were classified according to the anatomical
therapeutic chemical (ATC) classification. Drugs with the
following characteristics were identified: narrow therapeu-
tic index, cytochrome P450 inhibitor, cytochrome P450
inducer, cytochrome P450 substrate, activity over glycopro-
tein P, and those that prolong the QT interval.
Classification of potential drug interactions
The drugs administered in the first 24 hours of hospitaliza-
tion, the 50th length-of-stay percentile and at the time of
discharge were analyzed to identify potential drug-drug and
drug-enteral nutrition interactions using DRUG-REAXH
(Thomson MicromedexTM, Greenwood Village, Co, USA) 11.
This software has the appropriate sensitivity and specificity
to detect possible DIs.12,13 The software identifies the
interactions, provides information about the associated
clinical consequences or adverse reactions to drugs and
characterizes the interaction mechanism. The software
classifies the interactions in five categories according to
severity (contraindicated, severe, moderate, mild and
unknown), time of onset (immediate and delayed), and six
scientific documentation categories (excellent, good, fair,
poor, unlikely and unknown). The mechanism is classified as
pharmacokinetic or pharmacodynamic. For pharmacokinetic
interactions, the researchers identified the process involved
(absorption, distribution, metabolism or excretion) using the
interaction monograph provided by DRUG-REAXH .
Statistical analysis
The descriptive data were presented using the median
with the corresponding interquartile interval or as propor-
tions. Numerical variables were tested for normal distribu-
tion using the Kolmogorov-Smirnov and Shapiro-Wilt tests.
The Mann–Whitney non-parametric test was used for
comparisons when the t test did not meet the usual criteria
(normality and homoscedasticity). Comparisons between
categorical variables were performed using the chi-square
test without correction or with the Yates correction. The
odds ratio was also calculated. A value of p ,0.05 was
considered statistically significant. All statistical analyses
were performed using R 2.7.1.
RESULTS
Patient characteristics
The characteristics of the 299 patients included in the
study are presented in Table 1. The median age was 57 years,
with most participants (57.2%) younger than 60 years of age.
A little over half of the patients were female. The most
frequent diagnoses at the time of ICU admission were
circulatory system diseases. The average patient severity,
measured using SAPSII, was 25. The length of stay in the
ICU ranged from 5 to 72 days, with a median of 8 days.
Administered drugs
During 24 hours of hospitalization, 3,580 drugs containing
164 pharmacologically active substances were administered.
This was the largest number obtained among the three
hospitalization time points. The number of pharmacologi-
cally active substances used in the 50th length-of-stay
percentile was 157, and this number decreased to 107 at
discharge. Similarly, 3,575 drugs were administered in the
50th length-of-stay percentile, and this number diminished
to 2,883 at the time of discharge.
A median number of 12 medications were administered
per patient during the first 24 hours of hospitalization and
in the 50th length-of-stay percentile; the median number was
reduced to 10 at the time of discharge. The ATC system
groups with the largest number of administered drugs at
the three studied ICU time points were as follows: B-Blood
and blood-forming organs, C-Cardiovascular system, N-
Nervous system.
Potential Drug Interactions
The prevalence of potential DIs during the first 24 hours
of hospitalization in the 50th length-of-stay percentile and at
the time of discharge is shown in Table 2. There was no
evidence of any statistically significant difference between
the prevalence of DIs at the three studied hospitalization
time points. The largest number of DIs was identified in the
Table 1 - Clinical and demographic characteristics of the
299 ICU patients.
Clinical and demographic data Value
Age in years [median (interquartile interval)] 57(42–68)
,60 years [n (%)] 171(57.2)
.60 years [n (%)] 128(42.8)
Gender [female (%)] 151(50.5)
Length of stay in the ICU in days [median
(interquartile interval)]
8 (6–14)
Diagnoses [n (%)]
Circulatory system diseases 141(47.2)
Neoplasms 41(13.6)
Symptoms, signs and abnormal exam results not
classified elsewhere
25(8.4)
Digestive system diseases 24(8)
Respiratory system diseases 20(6.7)
Congenital defects, deformities and chromosome
aberrations
11 (3.7)
Others with a frequency #3% 37(12.4)
SAPS II [median (interquartile interval)] 25(19–34)
Charlson comorbidity index [median (interquartile
interval)]
4(1–4)
Pharmacotherapy
Number of medications administered within 24 hours
of hospitalization [median (interquartile interval)]
12(10–14)
Number of medications administered in the 50th
length-of-stay percentile [median (interquartile interval)]
12(10–14)
Number of medications administered at the time of
discharge [median (interquartile interval)]
10(7–12)
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50th length-of-stay percentile (753). The maximum number
of DIs per patient was 22 in the 50th length-of-stay
percentile, 17 at the time of discharge and 16 in the first
24 hours of hospitalization. The largest median number of
interactions per patient (2) was observed in the 50th length-
of-stay percentile.
In the 50th length-of-stay percentile, 170 types of potential
DIs were detected, 168 of which were drug-drug interac-
tions and two of which were drug-enteral nutrition
interactions. There were 137 types of drug-drug interactions
in the first 24 hours of hospitalization and 148 at the time of
discharge. In the first 24 hours of hospitalization, only one
type of drug-enteral nutrition interaction was detected, but
that number increased to three at the time of discharge.
The number of drugs administered was higher in patients
with potential DIs at the three investigated time points of
hospitalization. In the first 24 hours of hospitalization, the
median number of drugs administered to patients with a
potential DI was 13, (range 5 to 25); patients without a
potential DI were administered a median of 10 drugs(range
2 to 18). The median number of drugs administered to
patients with a possible DI in the 50th length-of-stay
percentile was also 13(range 4 to 25); patients without a
potential DI were given a median of 10 drugs( range 2 to 16).
At the time of discharge, the median number of drugs
administered to patients with a potential DI was 11(range 3
to 19); patients without a potential DI were given a median
of 7 drugs(range 2 to 14). The differences were statistically
significant at all three time points (p value ,0.001).
In terms of severity, most interactions were severe or
moderate. With respect to onset, delayed interactions were
the most prevalent, with frequencies of greater than 50%
observed at the different times of hospitalization. Most of
the scientific evidence supporting possible interactions was
good or excellent. Pharmacodynamic interactions presented
a subtle predominance in relation to pharmacokinetic
interactions. The highest frequency (61.4%) was detected in
the first 24 hours of hospitalization. Among the pharmaco-
kinetic mechanisms of the potential DIs, the most frequent
process was metabolism, which corresponded to up to 82.5%
of the interactions identified in prescriptions of the first
24 hours of hospitalization. The frequency of interactions
with the capacity to induce therapeutic failure ranged from
17.5–19.5% during the three time points, with the highest
value detected among the discharge prescriptions.
The pharmacotherapy factors associated with the occur-
rence of potential DIs and their respective odds ratios are
presented in Table 3. Only inducers of cytochrome P450,
drugs that prolong the QT interval and drugs from group C
of the ATC (cardiovascular system) were significantly
associated with potential DIs at the three time points
assessed during hospitalization. In the first 24 hours of
hospitalization, a potential DI association was discovered
between drugs with a narrow therapeutic index and drugs
from ATC group N. The use of drugs from groups J, L, and
N and those with a narrow therapeutic index was
significantly associated with a potential DI in the 50th
length-of-stay percentile. At the time of discharge, inhibitors
of cytochrome P450, drugs that affect glycoprotein P and
drugs from groups J and L were significantly associated
with potential DIs.
The length of stay was significantly greater among
patients who presented one or more potential DI in the
first 24 hours of hospitalization than in those without a
potential DI (average of 8 days compared to 7 days;
p,0.001). The same trend was observed in the 50th length-
of-stay percentile (average of 8 days compared to 6 days;
p,0.0010).
The ten most frequent severe and moderate interactions
are presented in Table 4. The severe interaction between
fentanyl and midazolam was the most frequent DI during
Table 2 - Prevalence of potential drug interactions in the
299 ICU patients.
Variable Value
First 24 hours of hospitalization
Number of patients with a potential DI (%) 205(68.6)
Total number of potential DIs 552
Types of DIs 138
Number of potential DIs per patient [median
(interquartile interval)]
1(0–3)
50th length-of-stay percentile
Number of patients with potential DIs (%) 221(73.9)
Total number of potential DIs 753
Types of DIs 170
Number of potential DIs per patient [median
(interquartile interval)]
2(0–4)
Discharge
Number of patients with potential DIs (%) 208(69,6)
Total number of potential DIs 610
Types of DIs 151
Number of potential DIs per patient [median
(interquartile interval)]
1(0–3)
Table 3 - Factors associated with the occurrence of potential DIs in the ICU.
First 24 hours 50th length-of-stay percentile Discharge
Predictive factors OR CI 95% p value OR CI 95% p value OR CI 95% p value
Narrow therapeutic index 4.4 1.4–3.9 0.0061 3.6 0.9–4.1 0.0393 2.3 0.9–5.7 0.0991
Cytochrome P450 inducer 3.0 1.8–5.1 ,0.0011 2.0 1.2–3.6 0.0121 2.2 1.3–3.9 0.0031
Cytochrome P450 inhibitor 1.5 0.2–11.0 0.6513 4.4 0.6–38.3 0.1143 6.6 2.3–20.0 ,0.0011
Modulation of glycoprotein P 2.2 0.0–81.2 0.5313 8.8 0.8–223.0 0.0563 9.4 2.4–43.7 ,0.0013
Drugs that prolong the QT interval 2.2 1.2–4.2 0.0101 1.9 1.1–3.5 0.0301 2.5 1.3–4.7 0.0031
ATC Group B ND ND ND 8.8 0.8–223 0.0563 4.0 0.8–21.5 0.0593
ATC Group C 3.1 1.7–5.6 ,0.0011 4.1 2.1–7.8 ,0.0011 9.2 5.0–17.0 ,0.0011
ATC Group J 1.3 0.8–2.3 0.2931 1.9 1.1–3.4 0.0201 1.8 1.1–3.1 0.0291
ATC Group L 1.7 0.6–4.4 0.3591 4.9 1.4–20.5 0.0091 9.3 2.1–57.3 0.0011
ATC Group N 6.4 3.3–12.5 ,0.0011 2.8 1.5–5.2 0.0011 1.6 0.9–2.8 0.0931
ND – not determined because every patient in the study used at least one medication of this ATC Group. CI- Confidence interval
1: Chi-square test with Yates correction; 2: Chi-square test; 3: Fisher’s exact test. OR - Odds ratio
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the first 24 hours of hospitalization. In the 50th length-of-stay
percentile and at the time of discharge, the most frequent
severe interaction was between captopril and potassium
chloride. Most of the ten most prevalent interactions in the
first 24 hours of hospitalization involved drugs from ATC
group N. Conversely, the most severe interactions at the
time of discharge and in the 50th length-of-stay percentile
involved drugs from groups C and J.
The main moderate interactions in the first 24 hours of
hospitalization also involved midazolam. Moderate interac-
tions prevailed in the 50th length-of-stay percentile and at
discharge and were caused by drugs from groups C, J, and L.
The most prevalent severe and moderate interactions
were those involving anticoagulants and platelet aggrega-
tion inhibitors, which are group B drugs.
DISCUSSION
This study demonstrated a 70% prevalence of potential
DIs at the investigated ICU at all three time points of
hospitalization; the prevalence of the DIs did not depend on
the time point studied. Quantitative studies demonstrating
the magnitude of DIs in the ICU are scarce.14 The overall
prevalence of DIs in the ICU, as described by other authors,
has been shown to range between 44.3% and 87.9%.14-16
Differences in study design, the studied casuistic, and
software sensitivity and specificity make it difficult to
compare our study with previous studies.
Within the context of intensive care, it is important to
investigate potential drug-drug interactions as well as
potential drug-enteral nutrition interactions. The present
study showed a low incidence of drug-enteral nutrition
interactions, with the highest occurrence observed in the
50th length-of-stay percentile and at the time of discharge.
However, it should be stressed that the potential drug-
enteral nutrition interactions have a clinical impact and can
affect the pharmacotherapeutic outcomes planned for the
patient. The drug-enteral nutrition interactions identified in
this study involved three drugs with a narrow therapeutic
index (phenytoin, levothyroxin and warfarin), which
demonstrates the clinical importance of these potential
interactions.17,18
The present study also showed that the prevalence of
potential DIs was associated with the number of drugs
administered. Although the number of drugs administered
at the time of discharge was reduced, the association with
the occurrence of interactions remained significant. The
number of medications has been shown to be a predictive
factor for the occurrence of DIs at hospitals, both in the ICU
and in internal medicine units 6,15,19,20.
The administration of cytochrome P450 inhibitors and
inducers and the drugs that affect glycoprotein P was
Table 4 - The ten most prevalent potential drug interactions.
Drug Interaction First 24 hours 50th length-of-stay percentile Discharge
Severe n % n % n %
Fentanyl + Midazolam 103 36.1 62 19.1 36 15.6
Captopril + Potassium Chloride 24 8.4 67 20.6 71 30.7
Acetylsalicylic Acid + Heparin 16 5.6 26 8.0 25 10.8
Clonazepam + Morphine 14 4.9 16 4.9 6 2.6
Clopidogrel + Enoxaparin 10 3.5 - - 5 2.2
Fentanyl + Morphine 10 3.5 - - - -
Midazolam +Morphine 10 3.5 - - - -
Fentanyl + Morphine 10 3.5 - - - -
Fentanyl + Prometazine 10 3.5 14 4.3 - -
Morphine +Prometazine 6 2.1 - - - -
Ciprofloxacin + Insulin - - 11 3.4 6 2.6
Fentanyl + Fluconazole - - 10 3.1 10 4.3
Amiodarone + Fentanyl - - 9 2.8 - -
Sulfametoxazole +Trimetroprim + Fluconazole - - 9 2.8 - -
Clonidine + Propranolol - - 7 2.2 - -
Potassium Chloride + Spironolactone - - - - 8 3.5
Captopril + Spironolactone - - - - 5 2.2
Amiodarone + Ciprofloxacin - - - - 5 2.2
Moderate
Furosemide + Hydrocortisone 12 6.9 22 7.1 7 2.4
Midazolam + Phenytoin 10 5.7 - - - -
Ciprofloxacin + Hydrocortisone 9 5.2 16 5.1 6 2.1
Fentanyl + Phenytoin Phenytoin 8 4.6 - - - -
Acetylsalicylic Acid + Enoxaparin 8 5.6 9 2.9 8 2.8
Fluconazole + Midazolam 7 4.0 - - - -
Midazolam + Omeprazole 6 3.4 - - - -
Methylprednisolone + Tacrolimus 5 2.9 - - - -
Furosemide + Gentamicin 5 2.9 - - - -
Dexamethasone + Phenytoin 5 2.9 - - - -
Captopril + Furosemide - - 17 5.4 21 7.3
Omeprazole + Tacrolimus - - 8 2.6 8 2.8
Fluconazole + Tacrolimus - - 8 2.6 8 2.8
Cyclosporine + Sulfamethoxazole+Trimethoprim - - 8 2.6 11 3.8
Hydrochlorothiazide + Propranolol - - 7 2.2 - -
Captopril +Hydrochlorothiazide - - 7 2.2 8 2.8
Hydrocortisone + Phenytoin - - 6 1.9 6 2.1
Amiodarone + Clonazepam - - - - 6 2.1
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associated with the occurrence of DIs. The activities of
cytochrome P450 and glycoprotein P are determinants of
important pharmacokinetic processes in a significant num-
ber of drugs and are involved in the mechanisms respon-
sible for DIs with clinical significance in the ICU. The
integration between basic and clinical research is essential
for identifying the mechanisms and the severity of those
interactions, especially in the ICU.1,7
The administration of drugs with a narrow therapeutic
index was an important predictor of DIs. The pharma-
cotherapy of critically ill patients requires the use of
cyclosporine, tacrolimus, phenytoin, gentamicin and vanco-
mycin, in addition to other drugs with narrow therapeutic
indexes. The identified association was likely due to the use
of these drugs.
The association discovered between the occurrence of
DIs and the administration of drugs that prolong the
QT interval should be stressed because there is a growing
concern regarding these drugs due to the risk of cardiotoxi-
city with torsade de points and cardiac arrest.21,22 These
adverse events can be determined by potential pharmaco-
kinetic interactions that inhibit the metabolism of drugs
with this property or by pharmacodynamic synergism.
The metronidazol+amidorane, fluconazole+sulfametoxazole+
trimetroprim, fluconazole+haloperidol, and amiodarone+
haloperidol interactions detected in this investigation can
produce the mentioned adverse events.
The association of DIs with ATC group N drugs was
greater in the first 24 hours of hospitalization and involved
mostly drugs used for sedation. Knowledge regarding the
epidemiology of excessive sedation and its determinants,
both pharmacological and non- pharmacological, is essential
for achieving excellent and safe sedation levels.
Pharmacological factors include DIs and organic dysfunc-
tions that can change the plasma concentration of the
sedative.23,24
The use of immunosuppressive drugs in transplant
patients being treated in the ICU explains the observed
association of drugs from group L with the occurrence of
interactions in the 50th length–of-stay percentile and at the
time of discharge. Immunosuppressive therapy is a complex
of drugs with narrow therapeutic indices and has char-
acteristics that predispose it to interactions with other
medications.25
The use of antimicrobials is common in critically ill
patients due to the risk of nosocomial infection, and the
occurrence of pharmacodynamic and pharmacokinetic
interactions with this therapeutic class have been previously
reported.4,26,27 These factors contribute to the association
between the administration of drugs from group J and the
occurrence of interactions in the 50th length-of-stay percen-
tile and at the time of discharge.
Cardiovascular drugs are often involved in drug-drug
interactions.19,28 The characteristics of cardiovascular drugs
that predispose them to DIs and the prevalence of
cardiovascular diseases in the ICU are factors that explain
the identified association.
In agreement with a previous study performed in an ICU,
we found that patients with DIs had longer lengths of stay at
the ICU.15 This can be explained by the knowledge that
more drugs are administered during a prolonged hospita-
lization, which results in elevated chance for a DI.
Nevertheless, the cross-sectional design of the present study
did not allow the identification of any causal relationships
between the occurrence of a potential DI and the variables
studied.
The potential drug-drug interactions detected were
mostly severe and moderate with excellent and good
evidence. The drug-enteral nutrition interactions were all
of moderate severity. The clinical significance of a DI is
determined by the severity, the drug profile, the clinical
consequences for the patient and the available evidence for
the interaction.29,30
Among the mechanisms of the potential DIs, the
pharmacodynamic mechanism showed a subtle predomi-
nance over the other possible mechanisms indentified
among the ICU prescriptions. An analysis of the pharma-
cokinetic interactions showed that drug metabolism was the
main determinant pharmacologic process responsible for
these interactions. Therapeutic failures and adverse reac-
tions are negative outcomes associated with the identified
potential interactions. Considering this profile of interac-
tions, the prevention measures at the studied ICU should
include strategies such as adjustments of the drug dose,
avoidance of group use, observation of the therapeutic
response and clinical monitoring for the early detection of
adverse effects.31
With respect to the time of onset, delayed interactions
prevailed. The identification of these interactions at the time
of discharge is important because the effect of an interaction
may not appear until the patient has been transferred to
another hospital unit. The greatest concern is that the effect
will not appear until after hospital discharge. This situation
highlights the importance of the medication reconciliation
process for patient safety upon discharge from the ICU.
The severe fentanyl+midazolam interaction, classified by
DRUG-REAXH as a pharmacodynamic interaction, is based
on pharmacological synergism, in which an opioid analgesic
(fentanyl) and a benzodiazepinic (midazolam) are used for
sedation. In addition, this combination is used to provide
comfort and anxiety relief to critically ill patients on
mechanical ventilation. It is also used to synchronize the
patient and the ventilator and to optimize oxygenation.
Thus, this interaction is used in intensive care with a
therapeutic goal.23,32
The current tendency is to classify this interaction as
pharmacokinetic because fentanyl is a P4503A4 cytochrome
inhibitor and midazolam is metabolized by this enzymatic
system. An accumulation of alpha hydroxymidazolam
glucuronide, the active metabolite of midazolam, was
identified in patients with prolonged sedation who were
treated with midazolam plus inhibitors of P4503A4 cyto-
chrome or who had other risk factors that affect the
elimination of midazolam.23,24,32,33
Among other potential interactions detected in this study
that interfere with sedation or analgesia were fentanyl+
fluconazole, fluconazole+midazolam, fentanyl+morphine,
midazolam+morphine, clarithromycin+fentanyl and clari-
thromycin+midazolam.
Ensuring excellent sedation levels is one of the challenges
in intensive care, and this goal should be pursued by the
health team to avoid prolonged periods of mechanical
ventilation and to reduce the risk for pneumonia, which can
be acquired while on ventilation. To ensure the safety of
sedation and analgesia in the ICU, the multidisciplinary
team should implement the following evidence-based
strategies: the use of validated scales to evaluate the level
of sedation and delirium, the daily interruption of sedation
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and the design of sedation protocols. The referenced
sedation protocols should include DI identification and
monitoring.24,32
The severe captopril+potassium chloride interaction was
the most prevalent interaction at the time of discharge and
in the 50th length-of-stay percentile. The clinical conse-
quence of this interaction is hyperkalemia, which mainly
occurs in individuals with cardiac insufficiency, the elderly
and patients with renal insufficiency. A study performed at
a Swiss Hospital also demonstrated that the interaction
between potassium and angiotensin-converting enzyme
(ACE) inhibitors was included among the most prevalent
DIs at the time of discharge.34 Another study, which
determined the rate of development of hyperkalemia in
hospitalized patients, found a statistically significant differ-
ence between the rate of development in patients using an
ACE inhibitor and those using ACE inhibitors + a potassium
supplement.35 Hyperkalemia can also be caused by other
potential interactions detected in the present study, includ-
ing captoptril+spironolactone, potassium chloride+spirono-
lactone or losartam+potassium chloride.
It is common to use spironolactone and ACE inhibitors
simultaneously in the therapeutic arsenal for the treatment
of cardiac insufficiency.36 A pharmacoepidemiological
study performed at an internal medicine unit of a hospital
in Switzerland demonstrated a four-fold increase in
hyperkalemia when ACE inhibitors were combined with
spironolactone, as compared to isolated uses.36 Monitoring
of the plasma levels of potassium is a strategy used to
observe this interaction, which can cause severe arrhyth-
mias. A study performed at an ICU in South Brazil showed
that the captopril+spironolactone interaction was among
those with the most significant clinical importance.15
The interaction between ACE inhibitors and potassium
during hospitalization presents smaller risks than in
ambulatory, provided that continuous monitoring of potas-
sium levels and renal function is performed. Consequently,
this interaction is acceptable within the hospital environ-
ment. The risk of hyperkalemia increases when this
combination is prescribed to patients upon discharge from
the hospital, because they will be without laboratory
monitoring. Therefore, for these patients, it is recommended
that replacements for one of the drugs be evaluated to avoid
this DI.38
The combination of platelet aggregation inhibitors (low-
dose aspirin or clopidogrel) with heparins is associated with
an increased risk of bleeding, as compared to isolated
treatments. The risk-benefit relationship of this association
is positive due to improvements in anti-thrombosis efficacy
in patients with acute coronary syndrome and atrial
fibrillation.39,40 To assure the safety and effectiveness of
this treatment, patients should be monitored continuously.39
The association between the occurrence of a DI and the
administration of group B drugs is probably determined by
the frequency of this type of interaction in the ICU.
Concerning the complexity of the analyzed data and the
cross-sectional study design used in the present study, the
results should be considered with an awareness of their
limitations. Retrospective data collection can cause bias due
to the possibility of incomplete patient records. The present
study was developed at a single ICU, and therefore, it may
be difficult to generalize the results.
The probability of pharmacokinetic interactions involving
metabolism depends on the time of enzymatic inhibition or
induction. The inhibition of drug metabolism is immediate
(24–48 h), whereas induction is a slower process (7–
10 days).10,41 Because the analysis was performed without
considering the doses administered or the time of treatment,
it is possible that the prevalence of DIs was overestimated.
This investigation employed restrictive criteria for poten-
tial interactions with acetylsalicylic acid, which helped to
avoid overestimations of the interactions. In intensive care
practice, acetylsalicylic acid is usually used in low doses
and as a platelet aggregation inhibitor. Potential interactions
were excluded if the DRUG-REAXH software indicated that
they occurred at acetylsalicylic acid doses above 300 mg.
Some studies have not considered the heparin + aspirin
association to be clinically significant due to the low doses
used and minimal chances of bleeding.19,38 Based on studies
showing a risk of bleeding with low doses of aspirin, these
associations were included in the present study.42,43
The clinical manifestations of the DIs were not evaluated
in the present study, and therefore, the potential drug
interaction expression was used. Another limitation of the
current study was the use of software to identify potential
interactions. Drug interaction screening software typically
produces strong signal levels that can indicate a greater
prevalence of potential DIs. Therefore, it is important to
consider, in addition to the overall prevalence of DIs, the
magnitude of the interaction in the clinical context of
intensive health care, as well as in terms of severity and
associated adverse events.
CONCLUSION
This study demonstrated a high prevalence of potential
DIs in the ICU due to the complexity of pharmacotherapy.
The severe interaction between fentanyl and midazolam
was the most frequent interaction that occurred during the
first 24 hours of hospitalization. In the 50th length-of-stay
percentile and at the time of discharge, the most frequent
severe interaction was captopril and potassium chloride.
Positive associations were observed between the occur-
rence of a potential DI and the number of drugs, the length
of stay and the characteristics of the administered medica-
tions.
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